| Popis: |
Prognosis of patients with peritoneal carcinomatosis (PC) from gastrointestinal cancer is poor, with a median overall survival of only 3 months [1], [2], and a 5-year survival rate of less than 1% [3]. Furthermore, no survival advantage was found after gastrectomy and lymph node dissection in this context, and therefore simple gastrectomy without additional lymphadenectomy is the optimal strategy for patients with PC [4]. In addition, there is no standard treatment and no effective anticancer drug for peritoneal dissemination. At present, intravenous 5-fluorouracil (5-FU) has been used alone [5] or in combination with other anticancer drugs FAM [6] and FAMTX [7] for chemotherapy of advanced gastric cancer. However, systemic chemotherapy does not improve the survival of patients with peritoneal dissemination [8], [9], because only a small amount of drug reaches the peritoneal cavity after intravenous administration. |
